A First in Human Study of CMND-100 in Healthy and Alcohol Use Disorder (AUD) Subjects
Status:
NOT_YET_RECRUITING
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to find the tolerable dose and characterize the safety and pharmacokinetics/ pharmacodynamics (PK/PD) of single and repeated dose of CMND-100 in Healthy Volunteers (HV) and Subjects with Binge Drinking/Alcohol Use Disorder (AUD).
The secondary objective of this study is to preliminarily evaluate the efficacy of CMND-100 in reduction of drinking patterns and craving in subjects with binge drinking or/and moderate to severe AUD.